Fountain Life

The clinical premise underneath Fountain Life is genuinely contested: whole-body MRI screening of asymptomatic people produces incidental findings in a large share of subjects — systematic reviews put critical-or-indeterminate findings around a third of scans — and mainstream medicine (including Michigan Medicine and numerous radiologists) warns that this drives biopsies, anxiety, overdiagnosis, and unnecessary treatment of findings that would never have caused harm. That is not a fringe critique; it is the standard-of-care consensus, and it exposes Fountain Life to reputational, medico-legal, and eventually regulatory risk if screening harms are documented at scale. The business model is capital-intensive and hard to scale: each clinic requires expensive MRI and CT hardware, radiologists, and physicians, so growth consumes cash — the $18M Series B is modest against a multi-city buildout, and $108M total over five years is thin for a physical-footprint healthcare business. The market is inherently narrow, limited to consumers who will pay five figures a year out of pocket, and it is crowded — Function Health (now at a $2.5B valuation), Human Longevity, Prenuvo, Neko Health, and Ezra all chase overlapping affluent buyers, several with far more capital. Heavy dependence on Diamandis's and Robbins's personal brands is both the growth engine and a concentration risk.